Alterome Therapeutics Raises $132M in Series B Financing
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
Stay updated with breaking news from Vida Ventures. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
Proceeds support advancement of two next-generation precision oncology programs into clinical development within 12 monthsFinancing led by Goldman Sachs Alternatives with participation by Canaan Partners, Driehaus Capital Management, Invus, Digitalis Ventures, Blue Owl Capital, and existing investorsSAN DI...
Alterome Therapeutics, a biopharmaceutical company, has closed a $132m Series B financing round.
Cell therapies were first validated in cancer, but Kyverna Therapeutics aims to show they’re safe enough for autoimmune diseases. The biotech plans to deploy its IPO cash across clinical trials in lupus nephritis, multiple sclerosis, systemic sclerosis, and myasthenia gravis.
Bringing Taiwan to the World and the World to Taiwan